Dr. Martens’ (DOCS) Buy Rating Reaffirmed at Berenberg Bank

Dr. Martens (LON:DOCS)‘s stock had its “buy” rating reaffirmed by equities researchers at Berenberg Bank in a research note issued to investors on Friday, MarketBeat.com reports. They currently have a GBX 110 target price on the stock. Berenberg Bank’s price target indicates a potential upside of 61.76% from the company’s current price.

Dr. Martens Stock Performance

Shares of DOCS stock opened at GBX 68 on Friday. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.85. Dr. Martens has a twelve month low of GBX 59.15 and a twelve month high of GBX 97.05. The company’s 50-day moving average price is GBX 74.25 and its 200-day moving average price is GBX 70.89. The stock has a market cap of £650.88 million, a price-to-earnings ratio of 28.33, a PEG ratio of 6.40 and a beta of 0.26.

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.